feasibl
develop
prophylact
vaccin
sar
assess
compar
immun
respons
elicit
immun
mice
recombin
sar
spike
glycoprotein
sprotein
formul
differ
adjuv
given
differ
rout
young
age
mice
intranas
protollinformul
sprotein
vaccin
elicit
high
level
antigenspecif
igg
serum
compar
elicit
intramuscular
alumadsorb
sprotein
vaccin
serum
antibodi
shown
viru
neutral
intranas
immun
young
mice
protollinformul
vaccin
elicit
signific
level
antigenspecif
lung
iga
contrast
mice
immun
intramuscular
vaccin
antigenspecif
lung
iga
detect
follow
live
viru
challeng
age
mice
viru
detect
lung
intranas
immun
mice
contrast
intramuscularli
immun
mice
whose
lung
viru
titer
compar
observ
control
mice
sever
acut
respiratori
syndrom
sar
infecti
diseas
appear
spontan
china
late
spread
rapidli
part
world
probabl
air
travel
new
coronaviru
sarscov
identifi
caus
agent
sar
genom
sequenc
publish
outbreak
caus
approxim
sarsrel
case
mortal
rate
rel
high
death
rate
coupl
appar
eas
transmiss
sarscov
pose
seriou
public
health
threat
prompt
consider
effort
develop
safe
effect
prophylact
vaccin
use
event
reappear
diseas
sinc
emerg
sever
approach
use
develop
sar
vaccin
inactiv
whole
sar
viru
sequenti
inactiv
formaldehyd
treatment
uv
irradi
shown
stimul
neutral
protect
antibodi
respons
mice
immun
subcutan
anoth
whole
viru
vaccin
compris
formaldehydeinactiv
polyethylen
glycol
peg
precipit
sar
viru
given
intranas
mice
report
induc
virusspecif
lung
iga
serum
igg
howev
sar
vaccin
develop
focus
subunit
vaccin
use
sar
spike
glycoprotein
see
front
matter
elsevi
ltd
right
reserv
sprotein
shown
contain
viru
receptor
bind
domain
rbd
well
neutral
epitop
fragment
sprotein
contain
either
rbd
neutral
epitop
exampl
recombin
baculovirusexpress
sprotein
shown
capabl
induc
high
titer
neutral
antibodi
given
intramuscularli
mice
without
alum
recombin
sprotein
fragment
contain
rbd
induc
high
titer
neutral
antibodi
sarscov
use
booster
mice
prime
dna
vaccin
infect
sar
viru
thought
mediat
bind
angiotensinconvert
enzym
surfac
protein
found
lung
alveolar
epitheli
cell
vascular
endothelium
thu
would
highli
desir
effect
vaccin
induc
immun
respiratori
tract
well
serum
ie
mucos
system
immun
laboratori
approach
attempt
induct
mucos
immun
mice
subunit
vaccin
formul
proprietari
adjuv
protollinshigella
flexneri
lp
noncoval
associ
major
outer
membran
protein
neisseria
meningitidi
proteosom
mani
preclin
studi
intranas
administr
vaccin
compris
antigen
formul
protollin
shown
elicit
potent
mucos
well
system
immun
clinic
trial
protollin
alon
intranas
vaccin
shigella
diseas
show
safe
welltoler
human
volunt
thu
provid
success
elicit
appropri
immun
respons
preclin
studi
protollinformul
sprotein
vaccin
would
potenti
test
clinic
trial
human
sar
vaccin
report
document
preclin
feasibl
studi
mice
intranas
protollinformul
sprotein
compar
respons
elicit
phenotyp
elicit
intramuscular
alumadsorb
sprotein
vaccin
recombin
sprotein
purchas
protein
scienc
corpor
meriden
ct
protein
truncat
version
sprotein
sar
urbani
strain
delet
transmembran
cytoplasm
domain
carboxyl
terminu
express
baculoviru
express
system
purifi
previous
describ
develop
gmp
lot
protollin
contain
approxim
equal
weight
proteosom
flexneri
lp
strain
prepar
diafiltr
previous
describ
store
c
freshli
thaw
aliquot
sprotein
protollin
mix
approxim
h
prior
immun
mice
alumformul
sprotein
prepar
adsorb
freshli
thaw
sprotein
onto
vv
alhydrogel
accur
chemic
ny
anim
procedur
perform
canadian
council
anim
care
associ
assess
accredit
laboratori
anim
care
accredit
anim
facil
anim
protocol
receiv
prior
approv
facil
inhous
anim
care
committe
anim
hous
five
per
cage
hepa
filter
cage
food
water
avail
ad
libitum
except
challeng
studi
experi
perform
femal
balbc
mice
challeng
studi
perform
age
femal
balbc
mice
approxim
month
old
day
group
mice
immun
intranas
light
isofluran
anesthesia
l
l
per
nare
protollinformul
sprotein
contain
g
protollin
g
sprotein
twentyf
microlit
alumformul
sprotein
g
sprotein
adsorb
onto
vv
alum
given
mice
intramuscular
inject
hind
limb
control
group
inocul
intranas
either
pb
sprotein
g
protollin
g
alon
mice
receiv
second
dose
vaccin
control
day
initi
inocul
day
mice
euthan
co
asphyxi
exsanguin
lung
lavag
perform
spleen
asept
remov
process
vitro
restimul
splenocyt
quantit
releas
cytokin
sera
lung
lavag
fluid
store
c
assay
previous
describ
asept
harvest
spleen
mous
particular
group
pool
process
singl
cell
suspens
minim
essenti
medium
mem
incub
differ
concentr
sprotein
modif
method
describ
previous
cytokin
releas
cell
cultur
supernat
follow
incub
measur
quantit
elisa
use
opteia
kit
bd
bioscienc
per
manufactur
instruct
antigenspecif
serum
igg
lung
lavag
iga
measur
elisa
microtit
plate
coat
gml
sprotein
subsequ
elisa
procedur
perform
previous
describ
igg
iga
antibodi
concentr
serum
lung
lavag
fluid
mice
immunogen
studi
quantit
refer
standard
curv
igg
iga
includ
everi
plate
previous
describ
data
express
geometr
mean
titer
individu
mous
result
within
group
statist
signific
antibodi
concentr
differ
group
mice
assess
anova
analysi
logtransform
individu
mous
data
tukeykram
pairwis
comparison
age
balbc
mice
use
challeng
studi
day
group
mice
immun
intranas
light
ketamin
anesthesia
either
l
l
per
nare
protollinformul
sprotein
g
sprotein
g
protollin
intramuscularli
hind
limb
l
alumformul
sprotein
g
control
group
inocul
intranas
either
pb
sprotein
g
protollin
g
alon
mice
receiv
second
third
dose
vaccin
control
day
follow
initi
inocul
day
blood
collect
mice
measur
serum
igg
neutral
antibodi
day
seven
mice
group
euthan
blood
lung
lavag
fluid
collect
assess
antigenspecif
serum
igg
neutral
antibodi
lung
iga
lung
lavag
fluid
assay
antigenspecif
iga
duplic
dilut
mean
od
duplic
well
report
sampl
remain
mice
group
bled
challeng
intranas
inocul
tcid
sarscov
urbani
strain
volum
l
three
day
postchalleng
mice
euthan
lung
harvest
one
lung
anim
homogen
subsequ
determin
lung
viru
titer
lung
process
histopatholog
examin
method
modif
previous
publish
method
equal
volum
heattreat
sera
dilut
incub
tcid
viru
c
h
surviv
viru
mixtur
titer
cytopath
effect
cpe
assay
serial
dilut
plate
quadrupl
assay
perform
triplic
plate
serum
cpe
assay
ml
neutral
sampl
ad
directli
cell
cultur
plate
contain
cell
appropri
cell
densiti
vero
cellswel
plate
previou
day
plate
addit
ml
cell
growth
medium
contain
fetal
bovin
serum
ad
well
gentli
mix
incub
c
day
previous
determin
optim
time
requir
achiev
full
cytopath
effect
nontreat
infect
control
use
viru
tcid
unit
well
plate
score
visual
observ
cpe
cytotox
use
light
microscopi
cpe
grade
scale
indic
cytopath
effect
indic
complet
cytopath
effect
titer
calcul
use
reedmuench
equat
invers
last
dilut
serum
complet
protect
cell
cpe
consid
viru
neutral
titer
serum
result
express
geometr
mean
titer
calcul
replic
result
mice
within
treatment
group
infect
control
viru
titrat
viru
back
titrat
control
viru
deterior
assay
sera
includ
mix
equal
volum
viru
mem
control
treat
manner
sera
contain
sampl
one
lung
challeng
mous
homogen
tissu
fragment
allow
settl
vari
dilut
supernat
fluid
assay
triplic
infecti
viru
vero
cell
cpe
assay
titer
tcid
valu
calcul
use
reedmuench
method
young
balbc
mice
immun
g
sprotein
given
intranas
formul
g
protollin
intramuscularli
adsorb
onto
vv
alum
antigenspecif
serum
igg
lung
lavag
iga
measur
elisa
result
shown
fig
follow
two
immun
sprotein
alon
elicit
detect
antigenspecif
serum
igg
lung
iga
intranas
immun
control
mice
contrast
intranas
administ
sprotein
formul
protollin
induc
high
level
antigenspecif
serum
igg
level
induc
formul
g
protollin
compar
induc
alumformul
sprotein
p
induc
formul
sprotein
g
protollin
significantli
higher
elicit
alumadsorb
sprotein
p
furthermor
intranas
vaccin
elicit
level
antigenspecif
lung
iga
significantli
higher
background
specif
iga
detect
lung
mice
given
intramuscular
vaccin
antigenspecif
iga
respons
sprotein
appear
highli
depend
amount
protollin
formul
sprotein
formul
g
protollin
elicit
higher
level
iga
sprotein
formul
g
protollin
sera
mice
use
immunogen
studi
also
assay
neutral
activ
sarscov
intranas
intramuscular
sprotein
vaccin
elicit
detect
neutral
antibodi
significantli
higher
observ
control
mice
immun
sprotein
alon
pb
buffer
data
shown
weekold
mice
given
g
sprotein
either
intranas
protollin
g
without
intramuscularli
adsorb
onto
vv
alum
geometr
mean
antibodi
concentr
gml
igg
ngml
iga
confid
limit
group
calcul
report
assess
phenotyp
respons
elicit
intranas
intramuscular
vaccin
singl
cell
suspens
splenocyt
immun
mice
prepar
restimul
cultur
incub
sprotein
differ
concentr
concentr
cytokin
releas
cultur
media
determin
elisa
shown
fig
splenocyt
mice
immun
intranas
protollinformul
sprotein
respond
vitro
restimul
secret
high
concentr
moder
level
low
concentr
compar
intranas
immun
mice
splenocyt
mice
immun
intramuscular
inject
alumadsorb
sprotein
respond
vitro
restimul
secret
similar
level
level
higher
strikingli
concentr
sever
hundr
fold
higher
thu
cytokin
profil
elicit
intranas
protollinformul
sprotein
vaccin
consist
balanc
respons
respons
slightli
bias
toward
phenotyp
wherea
cytokin
profil
induc
intramuscular
inject
alumadsorb
sprotein
consist
respons
bias
toward
phenotyp
group
age
mice
immun
intranas
protollinformul
sprotein
intramuscularli
alumadsorb
sprotein
mice
immun
day
sera
collect
day
antigenspecif
igg
sera
determin
elisa
result
shown
fig
mice
given
g
unformul
sprotein
intranas
gener
detect
antigenspecif
serum
igg
titer
two
immun
respons
enhanc
follow
third
immun
howev
protollinformul
alumadsorb
sprotein
vaccin
elicit
significantli
higher
antigenspecif
antibodi
respons
compar
unformul
sprotein
p
day
notic
though
even
three
immun
either
vaccin
antigenspecif
serum
igg
titer
elicit
age
mice
approxim
lower
serum
igg
respons
achiev
immun
young
mice
two
dose
vaccin
antigenspecif
igg
detect
serum
control
mice
receiv
either
pb
buffer
protollin
alon
day
sera
also
test
viru
neutral
antibodi
shown
tabl
intranas
intramuscular
fig
antigenspecif
serum
igg
lung
iga
b
concentr
age
mice
given
g
sprotein
either
intranas
formul
protollin
g
intramuscularli
adsorb
onto
vv
alum
control
mice
given
protollin
g
alon
sprotein
g
alon
pb
intranas
serum
igg
calcul
geometr
mean
antibodi
concentr
gml
confid
limit
group
calcul
report
lung
iga
concentr
assay
limit
quantit
mean
record
od
report
vaccin
elicit
similar
level
viru
neutral
antibodi
higher
control
group
day
prior
challeng
mice
group
euthan
lung
lavag
collect
assess
antigenspecif
iga
lung
lavag
assay
duplic
dilut
mean
od
duplic
well
report
sampl
group
mean
calcul
shown
fig
antigenspecif
iga
level
significantli
background
detect
mice
given
protollinformul
sprotein
group
mice
od
indistinguish
background
day
remain
mice
group
challeng
intranas
inocul
live
sar
viru
urbani
strain
three
day
postchalleng
mice
euthan
one
lung
homogen
determin
viru
titer
lung
process
histopatholog
examin
signific
histopatholog
find
report
challeng
mice
viru
titer
measur
report
tabl
mice
immun
intranas
protollinformul
sprotein
significantli
lower
viru
titer
immun
intramuscularli
alumadsorb
sprotein
none
mice
immun
g
sprotein
formul
protollin
detect
viru
titer
lung
given
lower
g
dose
antigen
detect
titer
albeit
level
lower
titer
control
mice
given
salin
adjuv
alon
studi
report
initi
test
feasibl
develop
intranas
vaccin
sar
compar
respons
elicit
protollinformul
sprotein
vaccin
administ
intranas
mice
elicit
inject
alumadsorb
sprotein
vaccin
expect
previou
studi
proprietari
adjuv
protollin
data
immunogen
studi
confirm
two
dose
either
vaccin
intranas
vaccin
capabl
induc
antigenspecif
respons
mucos
compart
ie
antigenspecif
iga
lung
lavag
fluid
vaccin
elicit
compar
system
respons
also
previou
studi
phenotyp
respons
balanc
intranas
vaccin
wherea
inject
vaccin
elicit
respons
bias
toward
phenotyp
better
understand
signific
lung
iga
respons
challeng
studi
conduct
age
mous
model
model
propos
sar
chal
tabl
geometr
mean
titer
gmt
sar
viru
neutral
antibodi
sera
collect
day
prior
challeng
within
group
mean
lung
viru
titer
day
postchalleng
adjuv
protollin
pb
control
alum
g
g
g
g
g
sprotein
g
g
g
g
g
g
g
leng
studi
may
mimic
clinic
observ
sar
epidem
observ
advanc
age
independ
correl
poor
outcom
predictor
mortal
sinc
report
sar
viru
replic
mice
author
propos
age
mous
model
demonstr
use
hand
challeng
studi
balbc
mice
immun
three
time
either
intranas
protollinformul
sprotein
intramuscularli
alumadsorb
sprotein
vaccin
elicit
compar
level
antigenspecif
serum
igg
though
titer
achiev
three
immun
fell
short
factor
titer
achiev
two
immun
mice
vaccin
howev
surpris
given
welldocu
effect
age
humor
immun
system
antigenspecif
lung
iga
titer
also
lower
elicit
mice
accept
elisa
lower
limit
quantit
howev
od
valu
minim
dilut
lung
lavag
use
instead
titer
analys
measur
lung
iga
significantli
higher
sproteinspecif
iga
level
detect
mice
immun
intranas
protollinformul
sprotein
immun
intramuscularli
alumadsorb
sprotein
although
specif
serum
igg
level
age
mice
high
young
mice
sera
collect
third
immun
prechalleng
shown
possess
strong
neutral
activ
live
sar
viru
furthermor
measur
viru
titer
lung
challeng
mice
show
much
lower
viru
count
lung
mice
given
protollinformul
vaccin
compar
titer
lung
mice
given
alumadsorb
vaccin
control
treatment
fact
none
mice
immun
intranas
higher
g
dose
sprotein
formul
protollin
show
detect
viru
titer
lung
thu
qualit
correl
level
iga
lung
lavag
fluid
intranas
immun
mice
viru
titer
recov
lung
follow
subsequ
challeng
fact
mice
immun
alumadsorb
sprotein
also
develop
high
level
serum
neutral
activ
detect
lung
iga
significantli
higher
viral
lung
titer
intranas
immun
mice
strongli
support
concept
specif
lung
iga
titer
import
case
sar
perhap
potenti
critic
compon
protect
afford
immun
protollinformul
intranas
sprotein
vaccin
studi
demonstr
intranas
vaccin
compris
protollinformul
sprotein
clearli
better
protect
mice
age
mous
challeng
model
sar
infect
intramuscular
alumadsorb
sprotein
vaccin
data
indic
develop
intranas
protollinformul
sprotein
vaccin
protect
reemerg
sar
diseas
warrant
studi
would
includ
advanc
develop
antigen
adjuv
product
perform
preclin
toxicolog
nonhuman
primat
studi
earli
phase
clinic
trial
design
assess
vaccin
safeti
immunogen
